ACAP1 and melanoma: Analysis from the “Gide 2019” cohort revealed that low ACAP1 levels were also associated with inferior response, OS, and PFS in melanoma patients treated with anti-PD-1 alone or in combination with anti-CTLA-4 antibodies (Figure 9C).